More than 50 lawmakers from both parties are pressing CMS to scrap a Medicare proposal they say could slow down better cancer treatments and put new therapies in a regulatory chokehold. The fight centers on how the agency would treat certain updated versions of existing drugs under the Medicare Drug Price Negotiation Program, a policy created under the Inflation Reduction Act.
The lawmakers want CMS Administrator Dr. Mehmet Oz to pull the fixed-dose combination piece from the final rule. Their argument is pretty direct: if the government moves too fast to bundle improved medicines into negotiations, drugmakers may have less reason to build the next generation of treatments.
That concern came through in a Sept. 21 letter, where the group said the proposal would hit some advanced therapies almost immediately after FDA approval. They warned that this would not just affect the companies making the drugs, but also the patients who are waiting for easier, faster, and more effective options.
At the core of the dispute is a simple question of timing and classification. CMS says the policy is meant to stop drugmakers from making minor changes to old products just to dodge negotiated Medicare prices, while lawmakers say the agency is treating genuinely improved medicines like paperwork tricks.
The letter points to cancer care as the clearest example. Some newer immunotherapy options, lawmakers said, can replace long infusion sessions with a quick injection, which can be a big deal for patients who are already dealing with brutal schedules, long travel times, and the grind of treatment.
For patients in rural areas, that difference can be even bigger. A therapy that is easier to administer can mean less time on the road, less strain on family members, and better access to care that might otherwise be out of reach.
“If finalized, the proposed fixed-dose combination policy would subject these advancements to negotiation almost immediately after FDA approval, harming patient access as well as incentives to develop these improved therapies,” the lawmakers wrote. They also said patients fighting cancer should not be left waiting while Washington sorts out labels and pricing categories.
The lawmakers also argue that the FDA already handles these products as separate medicines, with separate clinical trials and approvals. In their view, CMS should follow that same logic and treat them as distinct drugs under the Medicare negotiation program instead of lumping them together.
That point matters because a drug can be scientifically new without being completely new from the government’s point of view. If CMS draws the line too broadly, lawmakers say, it could catch upgrades that actually improve outcomes and make treatment easier for real people, not just rearrange brand names on a chart.
There is also the money question, and lawmakers are not buying the savings pitch. They say CMS actuaries have not shown that this policy would deliver meaningful savings for taxpayers, which weakens the case for taking a risk on patient access and innovation.
“We strongly urge CMS to withdraw the fixed-dose combination proposal from the final rule,” the letter states. “The patients we represent need policies that expand access to lifesaving care and reward medical progress and innovation in the treatment of deadly diseases.”
The pushback cuts across party lines, with signers including Reps. John Joyce, R-Pa., Darin LaHood, R-Ill., Mike Kennedy, R-Utah, Tim Moore, R-N.C., Jim Costa, D-Calif., and Donald Davis, D-N.C., among others. CMS had not immediately commented, leaving the proposal stuck in the middle of a familiar Washington battle over costs, control, and who gets to decide what counts as progress.
